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Abstract
The occurrence of more than 200 diseases, including cancer, can be attributed to alcohol drinking. The global cancer
deaths attributed to alcohol-consumption rose from 243,000 in 1990 to 337,400 in 2010. In 2010, cancer deaths due to
alcohol consumption accounted for 4.2% of all cancer deaths. Strong epidemiological evidence has established the causal
role of alcohol in the development of various cancers, including esophageal cancer, head and neck cancer, liver cancer,
breast cancer, and colorectal cancer. The evidence for the association between alcohol and other cancers is inconclusive.
Because of the high prevalence of ALDH2*2 allele among East Asian populations, East Asians may be more susceptible to
the carcinogenic effect of alcohol, with most evidence coming from studies of esophageal cancer and head and neck
cancer, while data for other cancers are more limited. The high prevalence of ALDH2*2 allele in East Asian populations
may have important public health implications and may be utilized to reduce the occurrence of alcohol-related cancers
among East Asians, including: 1) Identification of individuals at high risk of developing alcohol-related cancers by screening
for ALDH2 polymorphism; 2) Incorporation of ALDH2 polymorphism screening into behavioral intervention program for
promoting alcohol abstinence or reducing alcohol consumption; 3) Using ALDH2 polymorphism as a prognostic indicator
for alcohol-related cancers; 4) Targeting ALDH2 for chemoprevention; and 5) Setting guidelines for alcohol consumption
among ALDH2 deficient individuals. Future studies should evaluate whether these strategies are effective for preventing the
occurrence of alcohol-related cancers.
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Background
Alcohol consumption in the world
According to the 2010 estimate published by the World
Health Organization, the global average alcohol consump-
tion for individuals aged 15 or older was 13.5 g of pure
alcohol per day [1], which is approximately equivalent to 1
can of beer (12 oz. or 355 ml with 5.0% alcohol content),
1 glass of wine (5 oz. or 148 ml with 12% alcohol content),
or 1 drink of distilled spirits (1.5 oz. or 44 ml with 40%
alcohol content). The level of alcohol consumption varied
by regions with the highest consumption found in Eastern
Europe and Russia, and the lowest consumption seen in
Southeast Asia, Middle East, and North Africa [1].
Alcohol was consumed most commonly in the form of
spirits (50.1%), followed by beer (34.8%) and wine (8.0%)
[1]. The WHO projected that by 2025, alcohol consump-
tion will continue to rise, particularly in the Western
Pacific Region, which includes countries in the East Asia,
unless public health policies are implemented to curb or
reverse the trend [1].
Alcohol-related disease burden
The occurrence of more than 200 diseases can be fully
or partially attributed to alcohol drinking [2, 3]. Alcohol
use was ranked as the fifth leading risk factor of disease
globally in 2010, moving up from eighth place in 1990
[4]. Alcohol-related cancer, liver cirrhosis, and injury
accounted for the majority of mortality attributed to al-
cohol consumption [3]. Together these three conditions
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caused 1,500,000 deaths worldwide, representing 2.8% of
all deaths [3]. The global cancer deaths attributed to
alcohol-consumption rose from 243,000 in 1990 to
337,400 in 2010 [3]. In 2010, cancer deaths due to alco-
hol consumption accounted for 4.2% of all cancer deaths
[3]. All evidence indicates that the health impact of alco-
hol has been on the rise and this trend will likely to
continue. In addition, the economic burden associated
with alcohol consumption can be tremendous. The
annual alcohol-related financial cost was estimated to be
US$249 billion for USA, CA$14.5 billion for Canada, GB
£21 billion for UK, AU$35 billion for Australia, NT$25.5
billion for Taiwan, and JP¥6300 billion for Japan [5–7].
Alcohol-related cancers: evidence from epidemiologic
studies
Table 1 summarizes the association between alcohol and
alcohol-related cancers
Head and neck cancer
The association between alcohol and head and neck can-
cer is one of the most studied and the results consist-
ently showed an increased head and neck cancer risk
associated with alcohol drinking. In a meta-analysis of
52 studies, Bagnardi et al. reported a positive trend in
the association between alcohol drinking and head and
neck cancer risk (light drinking: relative risk (RR) = 1.13,
95% confidence interval (CI): 1.00–1.26; moderate drink-
ing: RR = 1.83, 95% CI: 1.62–2.07; heavy drinking: 5.13,
95% CI: 4.31–6.10) [8]. In Western countries, approxi-
mately 39% of head and neck cancer can be attributed to
alcohol consumption (4% for alcohol drinking alone and
35% for the combined effect of alcohol and tobacco) [9].
Esophageal cancer
Alcohol consumption is a well-established risk factor of
esophageal cancer, particularly esophageal squamous cell
carcinoma. In the meta-analysis by Bagnardi et al, alco-
hol consumption showed a positive dose-response
relationship with esophageal squamous cell carcinoma
(light drinking: RR = 1.26, 95% CI: 1.06–1.50; moderate
drinking: RR = 2.23, 95% CI: 1.87–2.65; heavy drinking:
RR = 4.95, 95% CI: 3.86–6.34) [8]. In a meta-analysis of
17 studies by Jarl et al. the risk of esophageal cancer was
reduced to the level of never drinkers after 16.5 years of
alcohol cessation, suggesting that alcohol cessation is ef-
fective in reducing the risk of esophageal cancer [10].
Liver cancer
Alcohol is a known risk factor of liver cancer. Chuang et
al conducted a meta-analysis of 112 studies and showed
an increased risk of liver cancer among ever drinkers
compared to never drinkers (RR = 1.29, 95% CI: 1.16–
1.42) [11]. They also reported a dose-response relation-
ship for the positive association between alcohol
consumption and liver cancer (12 g of alcohol per day:
RR = 1.08, 95% CI: 1.04–1.11; 50 g of alcohol per day:
RR = 1.54, 95% CI: 1.36–1.74; 75 g of alcohol per day:
RR = 2.14, 95% CI: 1.74–2.62; 100 g of alcohol per day:
RR = 3.21, 95% CI: 2.34–4.40; and 125 g of alcohol per
day: RR = 5.20, 95% CI: 3.25–8.29) [11]. In addition, a
synergistic interaction between alcohol drinking and
hepatitis or diabetes on the risk of liver cancer was
observed [11].
Breast cancer
Several meta-analyses have examined the association
between alcohol consumption and breast cancer.
Jayasekara et al. reported a weak non-linear positive
association between alcohol drinking and breast cancer
while Bagnardi et al. observed that the risk of breast
cancer rose linearly with increasing level of alcohol con-
sumption [8, 12]. Chen et al. reported that 5 g of ethanol
from wine per day was associated with a reduced breast
cancer risk while the risk of breast cancer began to
increase with more than 10 g of ethanol from wine per
day [13]. Overall, studies agreed that high level of alco-
hol consumption is associated with an increased breast
Table 1 The association between alcohol and alcohol-related cancers
Cancer type Level of association
with alcohol
Summary of current literature
Head and neck cancer Strong With light drinking, the risk of head and neck cancer increases by 13%, while the risk increases by more
than 5 times with heavy drinking [8].
Esophageal cancer Strong With light drinking, the risk of esophageal cancer increases by 26%, while the risk increases by 5 times
with heavy drinking [8].
Liver cancer Strong Compared to never drinkers, the risk of liver cancer increases by 1.3 times among ever drinkers. With light
drinking, the risk of liver cancer increases by 8%, while the risk increases by more than 5 times with
heavy drinking [11].
Breast cancer Moderate Overall, studies agreed that high level of alcohol consumption is associated with an increased breast
cancer risk while the risk of breast cancer at low level of alcohol consumption may require further
investigation [8, 12, 13]
Colorectal cancer Moderate Light drinking is not associated with colorectal cancer while heavy drinking is associated with a 1.5
times increase in the risk of colorectal cancer [8, 12]
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cancer risk while the risk of breast cancer at low level of
alcohol consumption may require further investigation.
Colorectal cancer
Studies have consistently found a positive association
between alcohol consumption and colorectal cancer,
although the increased risk is modest in magnitude [8,
12]. A meta-analysis by Bagnardi et al. reported a linear
positive dose-response relationship between alcohol drink-
ing and colorectal cancer (light drinking: RR = 0.99, 95%
CI: 0.95–1.04; moderate drinking: RR = 1.17, 95% CI:
1.11–1.24; heavy drinking: 1.44, 95% CI: 1.25–1.65) [8].
Jayasekara et al. also reported a linear positive dose-
response relationship between alcohol drinking and colo-
rectal cancer and the highest level of alcohol consumption
was associated with a 1.5 times increase in colorectal
cancer risk compared to the lowest level of alcohol
consumption [12].
The evidence presented so far only considers the aver-
age risk of cancer associated with alcohol consumption.
Genetic background may determine an individual’s sus-
ceptibility to the carcinogenic effect of alcohol. Individ-
uals deficient in aldehyde dehydrogenase 2 (ALDH2), an
enzyme that converts acetaldehyde, a carcinogenic
metabolite of ethanol, to acetate, may have a higher risk
of alcohol-related cancers. Based on overwhelming epi-
demiological evidences, the International Agency for
Research on Cancer (WHO/IARC) has classified ethanol
in alcoholic beverage as a Group 1 chemical, which is
carcinogenic to humans [14, 15]. The IARC working
group further emphasized the strong evidence of acetal-
dehyde derived from alcohol metabolism as the mechan-
istic basis in causing upper aerodigestive track (UADT)
cancers in individuals with ALDH2 deficiency [14, 15].
The role of ALDH2 and its polymorphism
In human, alcohol metabolism involves two major
NAD-dependent enzymes, alcohol dehydrogenase
(ADH) and aldehyde dehydrogenase (ALDH). Alcohol is
first oxidized to acetaldehyde by ADH. Acetaldehyde is
then oxidized to non-toxic acetate by ALDH for excre-
tion. Among the different human ALDH isozymes,
ALDH2, a mitochondria enzyme, is the most efficient
enzyme to remove toxic acetaldehyde [16]. Greater than
90% of the consumed alcohol is detoxified by the first-
pass metabolism, especially in the liver where ALDH2 is
abundant, although ALDH2 is distributed and functional
in many other major organs and tissues [17]. A striking
genetic polymorphism that dramatically reduces ALDH2
enzyme activity and affects alcohol response is the
variant ALDH2*2 allele. The variant ALDH2*2 allele is
caused by a single point mutation (G to A) in exon 12,
which leads to an amino acid substitution from glutam-
ine to lysine (E487K) [18]. The normal ALDH2*1 allele
and the variant ALDH2*2 allele can be easily genotyped
by the determination of single nucleotide polymorphism
(SNP) rs671 from the human genome. Due to the tetra-
meric nature of the ALDH2 enzyme, the E487K muta-
tion exhibits a dominant negative phenotype and affects
both heterozygous and homozygous individuals who
carry the variant allele. In carriers of the ALDH2*2/*2
homozygous and ALDH2*1/*2 heterozygous genotypes,
the enzyme activity is nearly 0% and 17–38% of the nor-
mal activity, respectively [19]. Such dramatic reduction
in the capacity of acetaldehyde clearance leads to accu-
mulation of acetaldehyde in circulation even after a
moderate amount of alcohol intake [20]. Hence, the
ALDH2*2 variant causes the well-known Asian Alcohol
Flushing Syndrome which is characterized by facial
flushing, palpitation, tachycardia, nausea, and unpleasant
feelings when alcohol is consumed by these individuals
[21]. The ALDH2*2 variant is essentially absent among
the Europeans, but is highly prevalent among East
Asians [22]. Large scale genotyping and haplotype ana-
lysis of the ALDH2 gene has traced the origin of the
ALDH2*2 allele back to the ancient Pai-Yuei tribe about
2000–3000 years ago in Southeast China [23]. The
ALDH2*2 allele likely dispersed from its origin toward
East Asia with the highest frequencies in Southeastern
coastal regions of China (e.g. Guangdong, Fujian prov-
inces) and countries with historical Han migrations,
such as Taiwan, Japan, Korea and Singapore [23, 24].
The prevalence of the ALDH2*2 variant varies from 28%
(e.g in Korea) to as high as 45% (e.g. in Taiwan) in popu-
lations of these regions [23] and an estimated 560
million East Asians are carriers of ALDH2*2 [25]. The
ALDH2 deficiency is therefore one of the most common
and genetically uniform enzymopathies in human carried
by approximately 8% of the world population.
ALDH2 polymorphism and risk of alcohol-related
cancers
Many studies have investigated the role of ALDH2 poly-
morphism and its interaction with alcohol consumption
in the development of various cancers. The strongest
and most consistent findings have been observed for
head and neck cancer and esophageal cancer, while the
evidence for other cancers is more limited (Table 2).
Head and neck cancer
In a meta-analysis of six case-control studies (945 cases
and 2917 controls), Boccia et al. reported a reduced risk of
head and cancer among individuals with ALDH2*2/*2
genotype, likely due to the lower consumption of alcohol
among these individuals [26]. In addition, ALDH2*1/*2
genotype showed gene-environment interaction with the
level of alcohol consumption [26]. Compared to ALDH2*1/
*1, ALDH2*1/*2 was associated with an increased risk of
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head and neck cancer among moderate drinkers (odds ratio
(OR) = 1.68, 95% CI: 1.27–2.22) and heavy drinkers (OR =
3.57, 95% CI: 1.41–9.05), but not among never drinkers
(OR = 0.97, 95% CI: 0.65–1.46) [26]. Three of the four stud-
ies published after the meta-analysis all showed a synergis-
tic interaction between ALDH2*2 allele and alcohol
drinking to increase head and neck cancer risk [27–29] and
only one study did not observe such interaction [30]. Over-
all, studies have indicated that ALDH2 polymorphism can
modulate the association between alcohol drinking and
head and neck cancer risk.
Esophageal cancer
Zhao et al. conducted a meta-analysis of 31 case-control
studies and found that ALDH2*2/*2 was associated with a
reduced risk of esophageal cancer (OR = 0.69, 95% CI:
0.48–0.98) while ALDH2*1/*2 was associated with an in-
creased esophageal cancer risk (OR = 2.34, 95% CI: 1.75–
3.13) [31]. Individuals with ALDH2*2/*2 tend to avoid alco-
hol consumption due to the severe reaction after alcohol
drinking and this is likely the explanation for their reduced
risk of esophageal cancer. However, Zhao et al. reported
that among alcohol drinkers, ALDH2*2/*2 was associated
with an increased esophageal cancer risk (OR = 3.87, 95%
CI: 1.67–8.96) compared to ALDH2*1/*1 [31]. In addition,
the association between ALDH2*1/*2 and esophageal
cancer became stronger with higher level of alcohol con-
sumption (never drinker: OR = 1.21, 95% CI: 0.95–1.73;
light drinker: OR = 3.79, 95% CI: 3.04–4.72; heavy drinker:
OR = 6.50, 95% CI: 5.34–7.92) [31]. Overall, literature pro-
vides strong evidence to support the synergistic interaction
between ALDH2*2 allele and alcohol consumption to
increase the risk of esophageal cancer.
Liver cancer
Among the 10 studies that examined the association
between ALDH2*2 and liver cancer risk, 8 found no sig-
nificant association [32–39], 1 found an increased risk
among individuals with at least 1 copy of the ALDH2*2
allele [40], and 1 found an increased risk for heterozy-
gous individuals only [41]. Among the six studies that
examined the interaction between ALDH2*2 and alcohol
drinking on liver cancer risk, three found a synergistic
interaction between ALDH2*2 allele and alcohol con-
sumption to increase liver cancer risk [36, 37, 40], while
three found no such interaction [33, 34, 38]. Overall,
studies to date have consistently shown that ALDH2*2
does not independently contribute to liver cancer risk.
Whether ALDH2*2 can modify the association between
alcohol consumption and liver cancer risk requires fur-
ther investigation.
Breast cancer
There is limited evidence regarding the association
between ALDH2 polymorphism and risk of breast
cancer. To date, only three studies have examined the
role of ALDH2*2 in the development of breast cancer
and all found no association between ALDH2*2 and risk
of breast cancer [42–44]. In addition, Choi et al. and
Kawase et al. examined the association between
ALDH2*2 and risk of breast cancer stratified by alcohol
consumption status and observed no significant inter-
action between ALDH2*2 and alcohol consumption on
the risk of breast cancer [43, 44]. With only three studies
published to date, it may be premature to rule out the
role of ALDH2*2 in the occurrence of breast cancer;
however, evidence from the small number of published
studies to date does not support a significant association
between ALDH2*2 and breast cancer.
Colorectal cancer
Four studies, all from Japan, have investigated the associ-
ation between ALDH2 polymorphism and colon cancer
risk. Yokoyama et al. reported an increased risk of colon
cancer (OR = 3.35, 95% CI: 1.51–7.45) associated with
alcoholic carriers of ALDH2*2 allele compared to alco-
holics with homozygous wild type [32]. Murata et al.
reported that alcohol showed a stronger dose-response
Table 2 The association between ALDH2 polymorphism and alcohol-related cancers
Cancer type Level of association with
ALDH2 polymorphism
Summary of current literature
Head and neck cancer Strong Most studies showed a synergistic interaction between ALDH2*2 allele and alcohol drinking
to increase head and neck cancer risk [26–29].
Esophageal cancer Strong Overall, literature provides strong evidence to support the synergistic interaction between ALDH2*2
allele and alcohol consumption to increase the risk of esophageal cancer [31].
Liver cancer Weak Overall, studies to date have consistently shown that ALDH2*2 does not independently
contribute to liver cancer risk. Whether ALDH2*2 can modify the association between
alcohol consumption and liver cancer risk requires further investigation [32–41].
Breast cancer Weak Results from the only three studies published to date do not support a significant association
between ALDH2*2 and breast cancer [42–44].
Colorectal cancer Weak The role of ALDH2*2 in the development of colorectal cancer is inconclusive and all of
the studies conducted to date have a small sample size that resulted in insufficient statistical
power and lack of precision [32, 45–47].
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relationship with colon cancer among ALDH2*1/*2 indi-
viduals than among ALDH2*1/*1 individuals, although
the results were not statistically significant; in addition,
alcohol consumption was not associated with rectal can-
cer risk regardless of the ALDH2 genotype [45]. Matsuo
et al. reported that high level of alcohol consumption
was associated with an increased rectal cancer risk but
not colon cancer risk among individuals with ALDH2*1/
*2 [46]. Miyasaka et al. found no association between
ALDH2*2 and colon cancer and did not assess the inter-
action between ALDH2*2 and alcohol drinking on colon
cancer risk [47]. Overall, the role of ALDH2*2 in the
development of colorectal cancer is inconclusive and all
of the studies conducted to date have a small sample size
that resulted in insufficient statistical power and lack of
precision.
Public health implications
Alcohol flushing and its associated unpleasant feelings
due to acetaldehyde accumulation is a strong deterrent
against heavy drinking and alcoholism for ALDH2*2 car-
riers [48]. Many studies have demonstrated the protect-
ive effect against alcohol addiction and abuse by ALDH2
deficiency. For example, in 1982, Harada first showed
that among Japanese alcoholics, only 2% of the subjects
are ALDH2 deficient [49]. However, influenced by social,
cultural, and economic factors in the past few decades,
such protection against alcohol dependence and alcohol
abuse has gradually lost among the large populations of
ALDH2*2 carriers. An alarming rise in the proportion of
heavy drinkers who are carriers of ALDH2*1/*2 genotype
has been documented from the 1970 to 2010. In Japan,
the percent of ALDH2*2 alcoholics was 2.5% in 1979,
and has increased to 8.0% in 1986, 13.0% in 1992 [50],
13.0% in 1996–2000, 14.0% in 2001–2005, and 15.4% in
2006–2010 [51]. This rapid rise is further highlighted by
a recent study in Tokyo area, showing that 26% of the
heavy drinking men who consume >400 g of ethanol per
week are ALDH2*1/*2 heterozygotes [52]. In Taiwan, an
estimation from a 1999 study indicated that 17% of the
alcoholics are ALDH2*2 carriers [53]. It is therefore
anticipated that, without intervention, the health risk
and healthcare burden caused by heavy ALDH2*2 alco-
hol drinkers will become much more severe in the next
few decades. The rapid and dangerous rise in alcohol
consumption and dependence among ALDH2*2 carriers
also underlines an urgent need for new public health
policies and guidelines and active campaigns for public
education and awareness in high ALDH2*2 prevalent
countries. Given the strong association between ALDH2
polymorphism and certain alcohol-related cancers,
screening for ALDH2*2 allele may have several public
health implications, including: 1) Identification of individ-
uals at high risk of developing alcohol-related cancers; 2)
Incorporation of ALDH2 polymorphism screening into
alcohol cessation program for promoting alcohol abstin-
ence or reducing alcohol consumption; 3) Using ALDH2
polymorphism as a prognostic indicator for alcohol-
related cancers; 4) Targeting ALDH2 for chemopreven-
tion; and 5) Setting guidelines for alcohol consumption
among ALDH2 deficient individuals.
Identification of individuals at high risk of developing
alcohol-related cancers
Early detection is the key to reduce cancer mortality and
increase the chance for cure. However, it is not cost-
effective to screen the entire population. Because cancer
is a rare disease, even if a screening tool has a high sen-
sitivity and specificity, the positive predictive value
(PPV) (percent of individuals who test positive and actu-
ally have the disease) will still be low. For example, in
2012, East Asia was the region with the highest inci-
dence of esophageal cancer with an incidence of 11 per
100,000 [54]. With this incidence, using a screening tool
with 99% sensitivity and 99% specificity will generate a
PPV of only 1.1%. This means that for every 100 positive
cases detected by screening, only 1 case will actually
have esophageal cancer. This is not cost-effective and
valuable medical resources will be wasted. In addition,
many individuals will undergo unnecessary medical pro-
cedures due to positive screening results. To make the
screening more cost-effective, it would be important to
identify the high-risk population to increase PPV. For
example, if we can identify a population with an esopha-
geal cancer incidence of 1 per 100, using a screening
tool with 99% sensitivity and 99% specificity, the PPV
will increase from 1.1 to 50% (1 of the 2 individuals with
a positive screening result will actually have esophageal
cancer), which is a substantial improvement in cost-
effectiveness. Given the strong evidence for the synergis-
tic interaction between ALDH2*2 allele and alcohol
drinking in increasing the risk of several alcohol-related
cancers, screening for the carriers of ALDH2*2 allele
may be ideal for identifying individuals at high risk for
alcohol-related cancers. For example, Yokoyama et al.
have developed a health risk model for screening
esophageal cancer [55, 56]. The model included informa-
tion on alcohol drinking, ALDH2 genotype or facial
flushing after alcohol consumption, which is a physical
symptom strongly associated with ALDH2*2 allele,
cigarette smoking, and consumption of vegetables and
fruits [55, 56]. Using this health risk model, Yokoyama
et al. were able to identify individuals with higher risk of
developing esophageal cancer, with an esophageal cancer
detection of 2.9% in the high-risk group compared to
0.5% in the low-risk group [56]. Another study by
Koyanagi et al. built a risk prediction model of UADT
cancer that incorporated information on sex, age,
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alcohol drinking, cigarette smoking, and ALDH2 geno-
type and reported that the risk model had a good dis-
criminative ability with an area under the curve of more
than 0.8 [57]. In addition, they reported that heavy
drinkers with ALDH2*1/*2 genotype have a 20% cumula-
tive risk of developing UADT cancer by the age of
80 years, while other individuals have < 5% risk of devel-
oping UADT cancer by the age of 80 years [57]. These
studies suggest that ALDH2 genotype may be incorpo-
rated in a risk prediction model to identify individuals at
high risk of developing alcohol-related cancers, particu-
larly those cancers that are strongly influenced by gene-
environment interaction between alcohol and ALDH2,
such as head and neck cancer and esophageal cancer.
For other alcohol-related cancers, including liver cancer,
breast cancer, and colorectal cancer, for which the evi-
dence for the involvement of ALDH2 is more limited,
more studies are needed to evaluate the interaction
between ALDH2 polymorphism and alcohol drinking on
the risk of these alcohol-related cancers.
Incorporation of ALDH2 polymorphism screening into
alcohol cessation program
It is possible that the knowledge regarding ALDH2 geno-
type and the associated disease risk may motivate indi-
viduals to reduce alcohol consumption. Hendershot et
al. conducted a web-based genetic feedback intervention
trial incorporating information on ALDH2 genotype
[58]. They recruited 200 northeast Asian American col-
lege students and randomized them to control and inter-
vention groups. Individuals in the control group
received a web-based feedback session that included
normative information about behaviors of college stu-
dents [58]. Individuals in the intervention group received
different web-based feedback sessions according to their
ALDH2 genotype. Individuals with ALDH2*1/*1 received
risk information on alcohol dependence while individ-
uals with ALDH2*1/*2 received risk information on
alcohol-related cancers [58]. One month after the web-
based feedback session, individuals in the intervention
group showed significant reduction in the frequency and
the quantity of alcohol drinking while individuals in the
control group showed no significant change in drinking
behaviors [58]. This suggested that it may be feasible to
incorporate information on ALDH2 genotype and the as-
sociated disease risk into an alcohol cessation program
to effectively reduce the consumption of alcohol. How-
ever, the use of genetic information to change health
behaviors is complex and its effectiveness is still incon-
clusive [59]. For example, Smerecnik et al. conducted a
meta-analysis of nine studies and found that genetic test-
ing of genes associated with smoking-related diseases
had only a short-term effect on risk perception and mo-
tivation to quit smoking, which did not last with longer
follow-ups [60]. More studies are needed to determine
whether genetic testing of ALDH2 will achieve a long
lasting effect for reducing the consumption of alcohol. It
is possible that the outward physical symptoms, includ-
ing facial flushing, palpitation, tachycardia, and nausea,
associated with ALDH2*2 may serve as a strong re-
minder to maintain the motivation for reducing alcohol
consumption. In addition, more investigations are
needed to determine the optimal and culturally appro-
priate methods for delivering genetic information and
the related disease risks.
ALDH2 polymorphism as a prognostic indicator for
alcohol-related cancers
ALDH2 polymorphism may be used to predict the sur-
vival, recurrence, and development of second-primary or
other alcohol-related cancers for patients with alcohol-
related cancers, particularly for esophageal cancer and
head and neck cancer. Kawakita et al. reported that both
alcohol drinking and ALDH2*2 were not independently
associated with disease-free survival of head and neck
cancer [61]. However, there was a significant positive
dose-response between higher alcohol consumption and
poorer disease-free survival of head and neck cancer
among ALDH2*1/*1 individuals [61]. The exact bio-
logical mechanism underlying this relationship was not
clear and the authors speculated that patients with
ALDH2*1/*1 might continue to drink alcohol at a higher
level after head and neck cancer treatment, resulting in
their poorer outcomes [61]. Yokoyama et al. conducted
a follow-up study of 100 alcoholic men diagnosed with
esophageal squamous cell carcinoma and observed that
during the follow-period, individuals with ALDH2*1/*2
were at higher risk of developing metachronous squa-
mous cell carcinoma in the esophagus, oral cavity, phar-
ynx and larynx (age-adjusted hazard ratio = 3.38, 95% CI:
1.45–7.85; alcohol-adjusted hazard ratio = 4.27, 95% CI:
1.42–12.89) compared to individuals with ALDH2*1/*1
[62]. Due to limited number of studies investigating the
role of ALDH2*2 in the survival or recurrence of
alcohol-related cancers, it may be premature to consider
its clinical application. However, once such role of
ALDH2*2 has been proven, the follow-up schedule and
methods for alcohol-related cancer patients may be
tailored according to their ALDH2 genotypes to increase
survival and improve early detection of cancer recur-
rence or second primary cancer.
Setting guidelines for alcohol consumption among
ALDH2 deficient individuals
If an individual does not drink alcohol, the best recom-
mendation for alcohol consumption would be not to
start. If one does drink, the Dietary Guidelines for
Americans 2015–2020 recommends no more than 1
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drink (14 g of pure alcohol) per day for women and 2
drinks for men [63]. The definition of low-risk alcohol
consumption varies widely across different countries in
the world ranging from 10 g per day to 42 g per day for
women and 14 g per day to 56 g per day for men [64].
These guidelines do not consider the influence of
ALDH2 polymorphism on the association between alco-
hol drinking and cancer and the amount of alcohol that
is considered low risk may not be suitable for individuals
with ALDH2 deficiency. For example, in a study by Lee
et al., compared to never drinkers with ALDH2*1/*1,
drinking < 30 g of alcohol per day was associated with a
2.2 times increase in esophageal cancer risk for those
with ALDH2*1/*1, but the risk increased by 14.5 times
and 17.3 times, respectively, for those with ALDH2*1/*2
and ALDH2*2/*2 [65]. This showed that even with the
amount of alcohol considered as “light” or “moderate”
drinking, the increase in esophageal cancer risk could be
substantial for carriers of ALDH2*2 allele. Therefore,
when setting the level of low-risk alcohol consumption,
it is important to consider the increased susceptibility to
the carcinogenic effect of alcohol among carriers of
ALDH2*2 allele. This is particularly relevant for East
Asian countries where the prevalence of ALDH2*2 allele
is high. More studies are needed to quantify the dose-
response relationship between alcohol consumption and
risk of various cancers by ALDH2 genotypes, particularly
for esophageal cancer and head and neck cancer, for
both the risk is significantly increased by the synergistic
interaction between alcohol consumption and ALDH2*2
allele. Results from these studies will be important for
experts in the field and public health officials to decide
on the level of alcohol consumption that confers mini-
mum acceptable risk.
Chemoprevention by aldehyde dehydrogenase activators
Exposure to acetaldehyde, a volatile, reactive and com-
monly present compound from either physiological
conversion of alcoholic beverages or from the environ-
mental sources (such as cigarette smoke [66], food items
[67], automobile exhausts [68] etc.) is almost unavoid-
able. Considering the carcinogenicity of acetaldehyde
and the significantly increased risk for head and neck
cancer, esophageal cancer, and other cancers for
ALDH2*2 variant carriers, implementation of chemopre-
ventive strategies may be a worthwhile effort for specific
high-risk groups, such as ALDH2*2 individuals who are
heavy drinkers or smokers or industrial workers who
have a higher acetaldehyde exposure burden. One of the
chemopreventive strategies is enhancing the catalytic
activity of the aldehyde dehydrogenase enzyme for faster
acetaldehyde clearance. Recently, a group of novel small
molecule ALDH enzyme activators have been discov-
ered. These compounds may serve as pharmaceuticals
leads for the development of chemopreventive agents
based on their enhanced capability of acetaldehyde
removal. Alda-1 (N-(1,3- benzodioxol-5-ylmethyl)-2,6-
dichlorobenzamide) was the first identified potent select-
ive activator for ALDH2 [69]. The compound has been
tested and shown to be effective in several animal
models of human diseases related to excessive aldehyde
toxicity [70–72]. One of the unique features of Alda-1 is
that the compound not only increases the catalytic activ-
ity of the wild type ALDH2*1 enzyme, but can also cor-
rect the defect of the mutant ALDH2*2 enzyme [69, 73].
This feature is particularly useful for the development of
a chemopreventive drug specifically for the ALDH2*2
carriers and the targeted high-risk human groups [74].
Another useful ALDH activator is Alda-89 (5-(2-prope-
nyl)-1,3-benzodioxole) which was discovered as a select-
ive ALDH3A1 isozyme activator [75]. The ALDH3A1 is
not an enzyme that metabolizes acetaldehyde efficiently
under normal physiological condition. However, with the
addition of Alda-89, the catalytic activity of ALDH3A1
toward acetaldehyde could be increased by at least 5
folds [75, 76]. In an acute alcohol intoxication animal
model, it was demonstrated that Alda-89 was able to
recruit ALDH3A1 to assist the function of ALDH2 for
acetaldehyde detoxification in both wild type and
ALDH2*2 knock-in mice [76]. It is conceivable that
ALDH activators, like Alda-1 or Alda-89, can be devel-
oped in various forms for rapid clearance of acetalde-
hyde regardless of its source or presence in either saliva
or circulating blood. Such drugs could potentially have a
great utility in reducing the risk of cancer or cancer
recurrence, especially among the groups of high-risk in-
dividuals who are alcohol drinkers, cigarette smokers
and carriers of ALDH2*2 allele. Caution should also be
given in the design of a chemopreventive program using
aldehyde dehydrogenase activators, since it is not clear
whether by enhancing ALDH activity, there will also be
a risk of increased alcohol consumption among
ALDH2*2 subjects. Behavioral intervention studies and
risk assessment on alcohol consumption and cessation
similar to the study mentioned above by Hendershot et
al. [58] should be recommended and incorporated in the
design of such a chemopreventive program.
Conclusions
Given the rising consumption of alcohol around the
world, the incidence of alcohol-related cancers will
continue to rise, particularly in East Asian countries and
regions with high concentrations of East Asian immi-
grants, where the percentage of ALDH2 deficient indi-
viduals is high. Information regarding an individual’s
ALDH2 genotype may help establish effective public
health preventive strategies to reduce the occurrence
and improve the survival of alcohol-related cancers.
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Screening for carriers of ALDH2*2 allele may identify
high-risk individuals for alcohol-related cancers. These
high-risk individuals may be targeted for more frequent
screening of alcohol-related cancers, health education,
and alcohol cessation program. In addition, alcohol-
related cancer patients carrying ALDH2*2 may be at
higher risk for recurrence or developing second primary
cancer and thus follow-up plan with more clinical visits
may be required. Finally, chemo-preventive agent to
restore the function of ALDH2 enzyme may be consid-
ered to prevent the occurrence or the recurrence of
alcohol-related cancers among high-risk individuals.
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